1. Home
  2. KZIA vs GSIW Comparison

KZIA vs GSIW Comparison

Compare KZIA & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$10.79

Market Cap

161.5M

Sector

Health Care

ML Signal

HOLD

GSIW

Garden Stage Limited

HOLD

Current Price

$0.14

Market Cap

28.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KZIA
GSIW
Founded
1994
2016
Country
Australia
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
161.5M
28.6M
IPO Year
1999
2023

Fundamental Metrics

Financial Performance
Metric
KZIA
GSIW
Price
$10.79
$0.14
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$17.67
N/A
AVG Volume (30 Days)
292.8K
342.2K
Earning Date
12-26-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,199,108.00
$5,368,221.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
283.23
52 Week Low
$2.86
$0.09
52 Week High
$17.40
$1.79

Technical Indicators

Market Signals
Indicator
KZIA
GSIW
Relative Strength Index (RSI) 51.48 39.31
Support Level $8.91 $0.13
Resistance Level $12.20 $0.14
Average True Range (ATR) 2.36 0.01
MACD -0.45 -0.00
Stochastic Oscillator 32.10 18.97

Price Performance

Historical Comparison
KZIA
GSIW

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

Share on Social Networks: